A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1093

Enrollment

INDUSTRY

Sponsor class

Stopped Inability to meet protocol objectives

Conditions

Melanoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Nivolumab + Relatlimab Fixed Dose Combination

Sponsor

Bristol-Myers Squibb